Zenas BioPharma, Inc. ZBIO

About Zenas BioPharma, Inc. (ZBIO): stock profile, AI score and financials

Zenas BioPharma, Inc. (ZBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZBIO at 7.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,906 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (0.2) and free cash flow (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zenas BioPharma, Inc. reports quarterly revenue of $1.0M, net income of $-111.5M, free cash flow of $-57.2M. Top institutional holders of ZBIO by reported 13-F value include FMR, SR ONE CAPITAL MANAGEMENT, NEA Management Company, based on the most recent SEC filings. ZBIO trades on the Nasdaq exchange and files with the SEC under CIK 1953926. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zenas BioPharma, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1953926 →